6-Mercaptopurine augments glucose transport activity in skeletal muscle cells in part via a mechanism dependent upon orphan nuclear receptor NR4A3

American Journal of Physiology - Endocrinology and Metabolism

Volumn 305, Issue 9, 2013, Pages

  Liu, Qinglan ^a   Zhu, Xiaolin ^b   Xu, Lusheng ^b   Fu, Yuchang ^b   Garvey, W Timothy ^b,c  

^a University of Alabama at Birmingham   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^c BIRMINGHAM VA MEDICAL CENTER   (United States)

Author keywords

6 mercaptopurine; Akt substrate of 160 kDa; Gloucose transporter 4 translocation; Glucose transport; Insulin action; NR4A3; Skeletal muscle

Indexed keywords

AS160 PHOSPHOPROTEIN; DEOXYGLUCOSE; GLUCOSE TRANSPORTER 4; INSULIN; MERCAPTOPURINE; NUCLEAR RECEPTOR NR4A3; PHOSPHOPROTEIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CELL STIMULATION; CONTROLLED STUDY; GENE OVEREXPRESSION; GENE SILENCING; GENE TRANSLOCATION; GENETIC TRANSCRIPTION; GLUCOSE TRANSPORT; INSULIN SENSITIVITY; MOUSE; MUSCLE CELL; NONHUMAN; PRIORITY JOURNAL; RAT; SKELETAL MUSCLE; TARGET CELL;

6-MERCAPTOPURINE; AKT SUBSTRATE OF 160 KDA; GLOUCOSE TRANSPORTER 4 TRANSLOCATION; GLUCOSE TRANSPORT; INSULIN ACTION; NR4A3; SKELETAL MUSCLE;

3T3 CELLS; 6-MERCAPTOPURINE; ANIMALS; ANTIMETABOLITES; CELLS, CULTURED; DNA-BINDING PROTEINS; GLUCOSE; GLUCOSE TRANSPORT PROTEINS, FACILITATIVE; GLUCOSE TRANSPORTER TYPE 4; GTPASE-ACTIVATING PROTEINS; INSULIN RESISTANCE; MICE; MUSCLE FIBERS, SKELETAL; NERVE TISSUE PROTEINS; RATS; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTORS, STEROID; RECEPTORS, THYROID HORMONE; RNA; RNA, SMALL INTERFERING; STIMULATION, CHEMICAL; TRANSLOCATION, GENETIC;

EID: 84886998870     PISSN: 01931849     EISSN: 15221555     Source Type: Journal    
DOI: 10.1152/ajpendo.00169.2013     Document Type: Article

References (44)

1. Benton CR, Nickerson JG, Lally J, Han XX, Holloway GP, Glatz JF, Luiken JJ, Graham TE, Heikkila JJ, Bonen A. Modest PGC-1alpha overexpression in muscle in vivo is sufficient to increase insulin sensitivity and palmitate oxidation in subsarcolemmal, not intermyofibrillar, mitochondria. J Biol Chem 283: 4228-4240, 2008.
2. Cara CJ, Pena AS, Sans M, Rodrigo L, Guerrero-Esteo M, Hinojosa J, García-Paredes J, Guijarro LG. Reviewing the mechanism of action of thiopurine drugs: towards a new paradigm in clinical practice. Med Sci Monit 10: RA247-RA254, 2004.
3. Codina A, Benoit G, Gooch JT, Neuhaus D, Perlmann T, Schwabe JW. Identification of a novel co-regulator interaction surface on the ligand binding domain of Nurr1 using NMR footprinting. J Biol Chem 279: 53338-53345, 2004.
4. DeFronzo RA. Current issues in the treatment of type 2 diabetes. Overview of newer agents: where treatment is going. Am J Med 123: S38-S48, 2010.
5. DeFronzo RA. Pathogenesis of type 2 diabetes mellitus. Med Clin North Am 88: 787-835, ix, 2004.
6. Deshmukh A, Coffey VG, Zhong Z, Chibalin AV, Hawley JA, Zierath JR. Exercise-induced phosphorylation of the novel Akt substrates AS160 and filamin A in human skeletal muscle. Diabetes 55: 1776-1782, 2006.
7. El-Bitar MK, Muwakkit SA, Dabbagh O. Severe hypoglycemic seizures in a child receiving 6-mercaptopurine. J Pediatr Hematol Oncol 33: e75-e76, 2011.
8. Flaig R, Greschik H, Peluso-Iltis C, Moras D. Structural basis for the cell-specific activities of the NGFI-B and the Nurr1 ligand-binding domain. J Biol Chem 280: 19250-19258, 2005.
9. Frosig C, Rose AJ, Treebak JT, Kiens B, Richter EA, Wojtaszewski JF. Effects of endurance exercise training on insulin signaling in human skeletal muscle: interactions at the level of phosphatidylinositol 3-kinase, Akt, and AS160. Diabetes 56: 2093-2102, 2007.
10. Fu Y, Luo L, Luo N, Zhu X, Garvey WT. NR4A orphan nuclear receptors modulate insulin action and the glucose transport system: potential role in insulin resistance. J Biol Chem 282: 31525-31533, 2007.
11. Garvey WT, Maianu L, Zhu JH, Brechtel-Hook G, Wallace P, Baron AD. Evidence for defects in the trafficking and translocation of GLUT4 glucose transporters in skeletal muscle as a cause of human insulin resistance. J Clin Invest 101: 2377-2386, 1998.
12. Halonen P, Salo MK, Makipernaa A. Fasting hypoglycemia is common during maintenance therapy for childhood acute lymphoblastic leukemia. J Pediatr 138: 428-431, 2001.
13. Hummasti S, Tontonoz P. Adopting new orphans into the family of metabolic regulators. Mol Endocrinol 22: 1743-1753, 2008.
14. Jessen N, An D, Lihn AS, Nygren J, Hirshman MF, Thorell A, Goodyear LJ. Exercise increases TBC1D1 phosphorylation in human skeletal muscle. Am J Physiol Endocrinol Metab 301: E164-E171, 2011.
15. Klip A. The many ways to regulate glucose transporter 4. Appl Physiol Nutr Metab 34: 481-487, 2009.
16. Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, Nathan DM; Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 346: 393-403, 2002.
17. Kramer HF, Witczak CA, Fujii N, Jessen N, Taylor EB, Arnolds DE, Sakamoto K, Hirshman MF, Goodyear LJ. Distinct signals regulate AS160 phosphorylation in response to insulin, AICAR, and contraction in mouse skeletal muscle. Diabetes 55: 2067-2076, 2006.
18. Lansey MN, Walker NN, Hargett SR, Stevens JR, Keller SR. Deletion of Rab GAP AS160 modifies glucose uptake and GLUT4 translocation in primary skeletal muscles and adipocytes and impairs glucose homeostasis. Am J Physiol Endocrinol Metab 303: E1273-E1286, 2012.
19. Larance M, Ramm G, Stockli J, van Dam EM, Winata S, Wasinger V, Simpson F, Graham M, Junutula JR, Guilhaus M, James DE. Characterization of the role of the Rab GTPase-activating protein AS160 in insulinregulated GLUT4 trafficking. J Biol Chem 280: 37803-37813, 2005.
20. Lecka-Czernik B. Bone as a target of type 2 diabetes treatment. Curr Opin Investig Drugs 10: 1085-1090, 2009.
21. Maxwell MA, Muscat GE. The NR4A subgroup: immediate early response genes with pleiotropic physiological roles. Nucl Recept Signal 4: e002, 2006.
22. Mayor P, Maianu L, Garvey WT. Glucose and insulin chronically regulate insulin action via different mechanisms in BC3H1 myocytes. Effects on glucose transporter gene expression. Diabetes 41: 274-285, 1992.
23. Myers SA, Eriksson N, Burow R, Wang SC, Muscat GE. Betaadrenergic signaling regulates NR4A nuclear receptor and metabolic gene expression in multiple tissues. Mol Cell Endocrinol 309: 101-108, 2009.
24. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 356: 2457-2471, 2007.
25. Ohkura N, Ito M, Tsukada T, Sasaki K, Yamaguchi K, Miki K. Structure, mapping and expression of a human NOR-1 gene, the third member of the Nur77/NGFI-B family. Biochim Biophys Acta 1308: 205-214, 1996.
26. Ordentlich P, Yan Y, Zhou S, Heyman RA. Identification of the antineoplastic agent 6-mercaptopurine as an activator of the orphan nuclear hormone receptor Nurr1. J Biol Chem 278: 24791-24799, 2003.
27. Pearen MA, Eriksson NA, Fitzsimmons RL, Goode JM, Martel N, Andrikopoulos S, Muscat GE. The nuclear receptor, Nor-1, markedly increases type II oxidative muscle fibers and resistance to fatigue. Mol Endocrinol 26: 372-384, 2012.
28. Pearen MA, Muscat GE. Minireview: Nuclear hormone receptor 4A signaling: implications for metabolic disease. Mol Endocrinol 24: 1891-1903, 2010.
29. Pearen MA, Myers SA, Raichur S, Ryall JG, Lynch GS, Muscat GE. The orphan nuclear receptor, NOR-1, a target of beta-adrenergic signaling, regulates gene expression that controls oxidative metabolism in skeletal muscle. Endocrinology 149: 2853-2865, 2008.
30. Pearen MA, Ryall JG, Maxwell MA, Ohkura N, Lynch GS, Muscat GE. The orphan nuclear receptor, NOR-1, is a target of beta-adrenergic signaling in skeletal muscle. Endocrinology 147: 5217-5227, 2006.
31. Reaven GM. Pathophysiology of insulin resistance in human disease. Physiol Rev 75: 473-486, 1995.
32. Rose AJ, Richter EA. Skeletal muscle glucose uptake during exercise: how is it regulated? Physiology (Bethesda) 20: 260-270, 2005.
33. Sano H, Kane S, Sano E, Miinea CP, Asara JM, Lane WS, Garner CW, Lienhard GE. Insulin-stimulated phosphorylation of a Rab GTPaseactivating protein regulates GLUT4 translocation. J Biol Chem 278: 14599-14602, 2003.
34. 588 phosphorylation in skeletal muscle without sustained increases in kinase phosphorylation. J Appl Physiol 113: 1852-1861, 2012.
35. Sonoda J, Pei L, Evans RM. Nuclear receptors: decoding metabolic disease. FEBS Lett 582: 2-9, 2008.
36. Wang Q, Khayat Z, Kishi K, Ebina Y, Klip A. GLUT4 translocation by insulin in intact muscle cells: detection by a fast and quantitative assay. FEBS Lett 427: 193-197, 1998.
37. Wansa KD, Harris JM, Yan G, Ordentlich P, Muscat GE. The AF-1 domain of the orphan nuclear receptor NOR-1 mediates trans-activation, coactivator recruitment, and activation by the purine anti-metabolite 6-mercaptopurine. J Biol Chem 278: 24776-24790, 2003.
38. Wansa KD, Muscat GE. TRAP220 is modulated by the antineoplastic agent 6-Mercaptopurine, and mediates the activation of the NR4A subgroup of nuclear receptors. J Mol Endocrinol 34: 835-848, 2005.
39. Wu X, Wang J, Cui X, Maianu L, Rhees B, Rosinski J, So WV, Willi SM, Osier MV, Hill HS, Page GP, Allison DB, Martin M, Garvey WT. The effect of insulin on expression of genes and biochemical pathways in human skeletal muscle. Endocrine 31: 5-17, 2007.
40. Wu Z, Puigserver P, Andersson U, Zhang C, Adelmant G, Mootha V, Troy A, Cinti S, Lowell B, Scarpulla RC, Spiegelman BM. Mechanisms controlling mitochondrial biogenesis and respiration through the thermogenic coactivator PGC-1. Cell 98: 115-124, 1999.
41. Wu X, Garvey WT. Insulin action. In: Textbook of Diabetes (4th ed.), edited by Holt RG, Cockram C, Flyvbjerg A, and Goldstein B. Hoboken, NJ: Wiley-Blackwell, 2010, p. 104-125.
42. Zhao Y, Bruemmer D. NR4A orphan nuclear receptors: transcriptional regulators of gene expression in metabolism and vascular biology. Arterioscler Thromb Vasc Biol 30: 1535-1541, 2010.
43. Zhu X, Walton RG, Tian L, Luo N, Ho SR, Fu Y, Garvey WT. Prostaglandin A2 enhances cellular insulin sensitivity via a mechanism that involves the orphan nuclear receptor NR4A3. Horm Metab Res 45: 213-220, 2013.
44. Ziino O, Russo D, Orlando MA, Benigno V, Locatelli F, Arico M. Symptomatic hypoglycemia in children receiving oral purine analogues for treatment of childhood acute lymphoblastic leukemia. Med Pediatr Oncol 39: 32-34, 2002.